Abstract
Recent reports have focused on the difficulty in differentiating autoimmune hepatitis from chronic hepatitic C due to the high prevalenc of anti-HCV in autoimmune hepatitis. The aim of this study was to identify clinical, biochemical, and serological variables that would help distinguish these two diseases. Pretreatment clinical and biochemical variables were compared from 17 patients with steroid-responsive autoimmune chronic active hepatitis and 62 patients with chronic hepatitis C. Serum samples from these patients were tested for autoantibodies and for anti-HCV by first- and second-generation ELISA, recombinant immunoblot assay, and HCV RNA by polymerase chain reaction. Patients with autoimmune hepatitis were more likely to be symptomatic (94% vs 47%,P<0.005) and jaundiced (76% vs 0%,P<0.005) at the time of referral. Anti-HCV was found in 53% of patients with autoimmune hepatitis, but only two were positive by immunoblot assay and only one of these had detectable HCV RNA. Antinuclear antibody (ANA) was detected in 21% of patients with chronic hepatitis C, although usually at a lower titer than in autoimmune hepatitis (geometric mean titer=1:160 vs 1:500,P<0.003). Patients with chronic hepatitis C who were ANA positive were older than those who were ANA negative, although there were no other differences in clinical or biochemical features between these groups. In particular, there was no difference in response rate to antiviral therapy. Thus, autoantibodies are frequently found in chronic hepatitis C, especially in older subjects, but appear to be clinically insignificant. Anti-HCV is frequently present in autoimmune hepatitis but is rarely confirmed by tests of higher specificity. These findings have important implications in selecting patients for antiviral or immunosuppressive therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494–1500, 1989
Czaja A: Autoimmune chronic active hepatitis.In Chronic Active Hepatitis: The Mayo Clinic Experience. A Czaja, ER Dickson (eds). New York, Dekker, 1986, pp 105–126
Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner JG, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon-therapy for chronic hepatitis C: Randomized double-blind placebo-controlled trial. N Engl J Med 321:1506–1510, 1989
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, Jacobson IM, Pay J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 321:1501–1506, 1989
Soloway RD, Summerskill WJH, Baggenstoss AH: Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 68:820–833, 1972
Czaja A: Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4:1–12, 1984
Lindberg J, Lindholm P, Lundin P, Iwarson S: Trigger factors and HL-A antigen in chronic active hepatitis. Br Med J 4:77–79, 1975
Robertson DAF, Zhang SL, Guy EC: Persistent measles vivus genome in autoimmune CAH. Lancet 2:9–11, 1987
McFarlane IG, Smith HM, Johnson PJ, Bray GP, Bergani D, Williams R: Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factors or false-positive result? Lancet 335:754–757, 1990
Magrin S, Craxi A, Fabiano C, Fiorentino G, Almasio P, Palazzo U, Pinzello G, Provenzano G, Pagliaro L, Choo Q-L, Kuo G, Polito A, Han J, Houghton M: Hepatitis C virus replication in autoimmune chronic hepatitis. J Hepatol 13:364–367, 1991
Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649–654, 1992
Shindo M, Di Bisceglie AM, Cheung L, Shih JW-K, Cristiano K, Feinstone SM, Hoofnagle JH: Decrease in hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Ann Intern Med 115:700–704, 1991
Peters M, Black M: Alpha interferon treatment of chronic hepatitis C: Need for accurate diagnosis in selecting patients. Ann Intern Med 116:86–88, 1991
Nishiguchi S, Kuroki T, Ueda T, Fukuda K, Takeda T, Nakajima S, Shiomi S, Kobayashi K, Otani S, Hayashi N, Shikata T: Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med 116:21–25, 1992
Mendenhall CJ, Seeff L, Diehl AM, Ghosn SJ, French SW, Gartside PS, Rouster SD, Buskell-Bales Z, Grossman CJ, Roselle GA, VA cooperative Study Group: Antibodies to hepatitis B virus and Hepatitis C virus in alcoholic hepatitis and Cirrhosis: Their prevalence and clinical relevance. Hepatology 14:581–589, 1991
Gurian LE, Rogoff TM, Ware AJ, Jordan RE, Combes B, Gilliam JN: The immunologic diagnosis of chronic active “autoimmune” hepatitis: distinction from systemic lupus erythematosus. Hepatology 5:397–402, 1985
Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102:1406–1408, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fried, M.W., Draguesku, J.O., Shindo, M. et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Digest Dis Sci 38, 631–636 (1993). https://doi.org/10.1007/BF01316792
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01316792